Next Steps to Stage IIIB NSCLC Patient Case Awaiting Molecular Testing and Usability of Liquid Biopsy

Panelists discuss how molecular testing is crucial in guiding treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the prevalence of mutations like BRAF, KRAS, MET, RET, and EGFR, and their impact on selecting targeted therapies.

EP: 1.Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing

Related Videos